ALIOF Candidate Approved in Japan - Analyst Blog

By
A A A
Share |

Actelion Ltd . ( ALIOF ) recently announced the receipt of Japan's Ministry of Health, Labor and Welfare approval for epoprostenol "ACT" for the treatment of pulmonary arterial hypertension (PAH).

The product is marketed in the US as Veletri. In 2012, it gained marketing approval in Switzerland as Veletri and in Canada as Caripul. The candidate is currently under regulatory review in the EU.

Our Take

We are encouraged by Japan's approval of this candidate. We note that Actelion is progressing with its pipeline. Important pipeline candidates include ponesimod, Opsumit and cadazolid.

Ponesimod is being evaluated for plaque psoriasis. In Dec 2012, the company announced positive results from a phase II study for this indication. Results from the study showed that both doses of ponesimod (20 mg and 40 mg) achieved statistical significance. Actelion now plans to initiate a phase III study on ponesimod for the psoriasis indication.

In Apr 2012, Actelion reported positive results on Opsumit (macitentan) for the treatment of PAH. Actelion filed for US Food and Drug Administration (FDA) and European Medicines Agency (EMA) approval of Opsumit in the fourth quarter of 2012.

Cadazolid, for the treatment of clostridium difficile associated diarrhea (CDAD), is expected to move into phase III study in the current year. The decision to advance the candidate into late-stage development was based on an exploratory phase II dose-finding study.

Results showed that the effect of all doses of cadazolid were either numerically similar or better than Vancocin on primary endpoints, which included CDAD cure rates as well as sustained cure rates.

Actelion carries a Zacks Rank #3 (Hold). Currently, Immunomedics Inc. ( IMMU ), Alkermes plc. ( ALKS ) and Agenus Inc. ( AGEN ) carry a Zacks Rank #2 (Buy).



AGENUS INC (AGEN): Free Stock Analysis Report

ACTELION LTD (ALIOF): Get Free Report

ALKERMES INC (ALKS): Free Stock Analysis Report

IMMUNOMEDICS (IMMU): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: Investing , Business , Stocks

Referenced Stocks: AGEN , ALIOF , ALKS , IMMU

Zacks.com

Zacks.com

More from Zacks.com:

Related Videos

Stocks

Referenced

Most Active by Volume

152,099,280
  • $16.13 ▼ 1.59%
76,450,549
  • $59.72 ▲ 1.07%
57,375,391
  • $36.35 ▲ 6.26%
50,140,425
  • $26.93 ▲ 0.60%
49,201,544
  • $3.17 ▲ 2.59%
39,533,031
  • $86.18 ▲ 1.33%
36,760,050
  • $13.42 ▲ 2.84%
33,109,047
  • $26.12 ▲ 1.16%
As of 4/16/2014, 04:05 PM